Phase 2 Schizophrenia Trial, Recruiting NCT07410507 Sponsor: Eli Lilly and Company Condition: Schizophrenia
Back to Schizophrenia

Phase 2 Schizophrenia Trial, Recruiting

NCT07410507
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with schizophrenia according to established diagnostic criteria
  • People who are currently on a stable medication routine for schizophrenia
  • People whose schizophrenia has lasted more than 6 years and who have had at least one return of symptoms (relapse) in the past 3 years
  • People who have at least one reliable support person, such as a family member, social worker, caseworker, residential facility staff member, or nurse
  • People who are willing and available to attend all required study visits for the full duration of the trial, and who are willing to follow study procedures, which may include giving themselves injections of the study medication, storing and using the study medication as directed, keeping electronic or paper study diaries, and completing required questionnaires

Who may not be able to join:

  • People who have ever been diagnosed with bipolar disorder, borderline personality disorder, or any eating disorder
  • People who have had a moderate or severe problem with substance or alcohol use within the past 180 days (roughly 6 months) before the screening visit
  • People who have type 1 diabetes, or a history of diabetic ketoacidosis or a serious diabetic emergency involving very high blood sugar
  • People who are currently at risk of harming themselves or who are considered to have a significant risk of suicide
  • People who are already taking part in another clinical trial involving an investigational product or medical research that may not be compatible with this study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Phone: 1-317-615-4559

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
10 February 2026
Est. completion
1 November 2027

Where this trial is recruiting

🇦🇷 Argentina 🇧🇷 Brazil 🇨🇳 China 🇮🇳 India 🇯🇵 Japan 🇹🇼 Taiwan 🇺🇸 United States

Primary endpoints

Percent Change from Baseline in Body Weight in Participants with a Baseline Body Mass Index ≥25.0 Kilograms per Meter Squared (kg/m²)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov